Get started
Intellia Therapeutics, Inc.Intellia Therapeutics, Inc.Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

NTLA chart


Full chart

NTLA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.23 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.45 USD
Net income (FY)
‪−481.19 M‬ USD
Revenue (FY)
‪36.27 M‬ USD
Shares float
‪100.10 M‬
Beta (1Y)
3.12

Employees


Employees (FY)
526
Change (1Y)
−72 −12.04%
Revenue / Employee (1Y)
‪68.96 K‬ USD
Net income / Employee (1Y)
‪−914.81 K‬ USD

About Intellia Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
John M. Leonard
Website
intelliatx.com
Headquarters
Cambridge
Founded
2014
FIGI
BBG007KC7PB0
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NTLA news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where NTLA is featured.

See all sparks 

Frequently Asked Questions


The current price of NTLA is 12.05 USD — it has decreased by −0.41% in the past 24 hours. Watch Intellia Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Intellia Therapeutics, Inc. stocks are traded under the ticker NTLA.
NTLA stock has fallen by −9.67% compared to the previous week, the month change is a −13.93% fall, over the last year Intellia Therapeutics, Inc. has showed a −60.95% decrease.
We've gathered analysts' opinions on Intellia Therapeutics, Inc. future price: according to them, NTLA price has a max estimate of 128.00 USD and a min estimate of 14.00 USD. Watch NTLA chart and read a more detailed Intellia Therapeutics, Inc. stock forecast: see what analysts think of Intellia Therapeutics, Inc. and suggest that you do with its stocks.
NTLA reached its all-time high on Jun 30, 2021 with the price of 202.73 USD, and its all-time low was 9.18 USD and was reached on Mar 16, 2020. View more price dynamics on NTLA chart.
See other stocks reaching their highest and lowest prices.
NTLA stock is 3.21% volatile and has beta coefficient of 3.12. Track Intellia Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Intellia Therapeutics, Inc. there?
Today Intellia Therapeutics, Inc. has the market capitalization of ‪1.23 B‬, it has decreased by −7.84% over the last week.
Yes, you can track Intellia Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Intellia Therapeutics, Inc. is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
NTLA earnings for the last quarter are −1.34 USD per share, whereas the estimation was −1.39 USD resulting in a 3.61% surprise. The estimated earnings for the next quarter are −1.34 USD per share. See more details about Intellia Therapeutics, Inc. earnings.
Intellia Therapeutics, Inc. revenue for the last quarter amounts to ‪9.11 M‬ USD, despite the estimated figure of ‪8.28 M‬ USD. In the next quarter, revenue is expected to reach ‪9.29 M‬ USD.
NTLA net income for the last quarter is ‪−135.71 M‬ USD, while the quarter before that showed ‪−146.97 M‬ USD of net income which accounts for 7.66% change. Track more Intellia Therapeutics, Inc. financial stats to get the full picture.
No, NTLA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 526.00 employees. See our rating of the largest employees — is Intellia Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Intellia Therapeutics, Inc. EBITDA is ‪−527.52 M‬ USD, and current EBITDA margin is ‪−1.40 K‬%. See more stats in Intellia Therapeutics, Inc. financial statements.
Like other stocks, NTLA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Intellia Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Intellia Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Intellia Therapeutics, Inc. stock shows the strong sell signal. See more of Intellia Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.